

Exhibit 2

DuBord Brown, Renee

From: DBaker@kayescholer.com
Sent: Saturday, August 04, 2007 7:53 PM
To: DuBord Brown, Renee; Jordan, Jeremy
Cc: TFleming@kayescholer.com; HHeckel@kayescholer.com; HSuh@kayescholer.com; AElefano@kayescholer.com; DLopez@kayescholer.com; ReHenry@kayescholer.com
Subject: Roche's Counter Designations and Objections to Amgen's Designations
Attachments: Roche Counter Designations and Objections.pdf

Dear Counsel,

Attached please find Roche's Counter Designations and Objections to Amgen's Designations.

Thank you.

(See attached file: Roche Counter Designations and Objections.pdf)

Donna U. Baker
Senior Legal Assistant
Kaye Scholer LLP
425 Park Avenue
New York, New York 10022-3598
(212) 836-7954 (direct line)
(212) 836-8689 (main fax)
dbaker@kayescholer.com

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN DESIGNATIONS**EXHIBIT B****Amgen's Deposition Designations for Witnesses who may be called by Designation**

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
ITC					
Buch, Jean Pierre	85:9	87:1	O	54:2	54:10
				88:2	88:19
Dinella, Cynthia	9:16	40:19	O	81:13	82:6
	42:24	49:13	O	96:23	97:2
	49:20	58:5	O	108:16	109:25
	58:21	61:14	O	191:18	192:11
	62:5	63:14		235:4	235:22
	64:24	66:22		277:17	278:4
	67:6	68:16	O	280:12	280:17
	75:14	78:18	O		
	79:14	81:9			
	94:19	96:22	O		
	98:3	98:7			
	98:12	103:25	O		
	113:15	114:10	O		
	117:4	119:20	O		
	190:25	191:15	O		
	193:21	194:12			
	221:23	224:16	O		
	226:11	227:13	O		
	234:10	235:3			
	272:4	273:13	O		
	277:3	277:16	O		
Franzino, Joanne	9:12	15:25	O	16:1	16:25
	63:5	65:16	O	122:2	122:9
	79:7	83:21	O	122:12	122:13
				122:24	123:4
				123:7	
				123:15	123:20
				123:23	124:7
				125:2	125:12
				125:15	126:2
Joseph, Robert	12:21	13:17	O	16:24	16:25
	14:13	14:25		23:19	23:21
	16:3	16:23	O	25:5	25:12
	17:24	18:5	O	34:4	34:12
	19:11	20:21		53:21	53:23

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN'S DESIGNATIONS
EXHIBIT B
Amgen's Deposition Designations for Witnesses who may be called by Designation

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
	22:21	23:8	O	86:9	86:12
	23:13	23:18		96:23	96:24
	23:22	25:4	O	97:18	97:22
	26:5	26:24	O	111:7	111:20
	27:14	27:25		114:8	114:12
	28:8	28:12	O	115:21	116:8
	34:20	35:5	O	118:19	119:4
	37:11	39:8	O	127:13	127:25
	53:3	53:20	O	151:19	152:5
	58:3	59:6	O	164:3	164:16
	61:6	63:9	O	172:7	173:2
	63:24	64:13	O	178:12	178:25
	64:21	65:14	O		
	74:19	76:5	O		
	76:14	78:24	O		
	79:12	83:4	O		
	85:22	86:7			
	86:13	86:22			
	87:21	88:17			
	96:20	96:22			
	96:25	97:17	O		
	97:23	98:3			
	98:8	98:13			
	98:22	100:3	O		
	100:6	100:12			
	102:23	103:10			
	108:6	108:20	O		
	110:3	111:6	O		
	112:18	114:7	O		
	115:4	115:7			
	118:3	118:18	O		
	119:5	119:10	O		
	128:11	128:15	O		
	128:22	130:14	O		
	130:24	131:16			
	142:12	144:17			
	149:20	150:6	O		
	150:15	150:18			
	151:2	151:18	O		
	152:5	152:12	O		
	157:2	157:13	O		
	158:24	160:21	O		
	160:25	161:10			
	173:3	173:18			

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN'S DESIGNATIONS
EXHIBIT B
Amgen's Deposition Designations for Witnesses who may be called by Designation

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
	181:2	181:7			
Kingma-Johnson, Iris	7:23	10:12		177:17	177:18
	16:12	16:18		194:13	194:14
	177:10	177:24	O	195:6	195:7
	193:4	197:21	O	195:25	196:2
				196:13	196:14
				196:25	197:2
				197:10	197:11
				197:18	197:19
Knickmeier, Marcus	75:21	76:11		16:14	17:8
	84:22	85:20	O	17:11	17:12
	86:11	89:9	O	85:13	85:15
	120:23	121:20		87:10	
	122:25	125:16	O	88:15	
	125:18	126:2	O	89:6	
	126:5	126:13	O	125:17	
	126:18	127:19	O	126:3	126:4
	129:2	129:7		126:14	126:17
	129:9	129:11		130:13	130:14
	129:13	131:12	O	130:20	130:21
	137:11	140:22	O	130:25	
				140:18	140:20
Much, Barbara	7:3	7:13	O	22:7	22:11
	22:12	22:15	O		
Shah, Nimish	7:20	8:10		37:12	
	9:19	9:23		37:14	37:16
	10:3	10:19		38:5	39:13
	11:4	11:13		39:17	39:18
	37:8	37:11	O	40:23	40:24
	37:13	37:13		45:11	45:13
	37:17	38:4		45:20	45:21
	38:7	39:16		87:21	87:22
	39:19	40:22	O	87:24	88:4
	44:25	45:8		90:19	90:20
	45:9	45:10		105:18	105:21
	45:14	45:19		109:20	109:22
	45:22	45:24		110:11	110:12
	87:7	87:20	O	111:16	111:18
	87:23	87:23		111:22	111:23
	88:18	88:23	O	114:24	115:3

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN'S DESIGNATIONS
EXHIBIT B
Amgen's Deposition Designations for Witnesses who may be called by Designation

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
	88:25	89:11			
	89:12	89:24			
	90:8	90:18	O		
	90:21	90:24	O		
	90:25	91:2			
	109:4	109:19			
	110:3	110:10			
	110:13	110:13			
	111:10	111:15			
	111:19	111:21			
	111:24	111:25			
Schorle, Axel	6:15	7:13	O	24:5	26:5
	11:4	11:20	O		
	15:11	15:19	O		
	17:21	20:2	O		
	26:6	27:1	O		
Van der Auwera, Philippe	7:18	8:10		14:2	14:3
	8:16	8:18		14:19	
	9:5	9:11		15:14	15:15
	9:15	10:3		16:15	16:16
	10:5	13:21		17:13	17:14
	14:15	14:18	O	81:5	81:12
	14:20	15:10		105:15	105:16
	15:17	15:17		107:13	107:14
	16:9	16:14		107:22	
	16:17	17:12		107:24	107:25
	17:15	18:9		109:6	109:7
	24:9	24:17		109:14	109:15
	24:20	25:4		110:5	110:8
	39:10	40:11		111:23	
	41:2	41:8		118:4	
	41:15	42:6		118:14	118:20
	42:10	43:6		120:6	120:7
	43:13	44:2		121:17	121:23
	80:5	81:4		125:9	
	81:14	81:16		130:3	130:4
	83:15	83:20		136:3	
	87:19	87:25		136:18	136:19
	88:5	88:9		137:3	
	105:11	105:14		138:1	
	105:17	105:18		139:11	

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN'S DESIGNATIONS
EXHIBIT B
Amgen's Deposition Designations for Witnesses who may be called by Designation

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
	105:19	105:24		154:5	
	107:8	107:12		154:13	
	107:15	107:21		155:17	155:18
	107:23	107:23		157:13	157:14
	108:1	108:9		159:19	
	108:24	109:5		160:2	
	109:8	109:13		160:19	
	109:16	110:4		162:8	
	110:9	111:2		164:1	
	111:9	111:18		164:25	165:2
	111:24	111:25		165:8	165:9
	112:14	114:5		165:21	165:24
	117:2	117:5		166:14	
	117:8	117:11		167:13	167:15
	117:16	117:16		171:8	171:9
	117:21	118:3	O	193:19	193:20
	118:5	118:13		194:19	
	119:4	120:5		200:10	200:12
	120:8	121:16		200:14	200:15
	121:25	122:2		200:21	
	124:9	124:18			
	125:5	125:9	O		
	125:11	125:20			
	128:22	130:2			
	130:5	130:6			
	135:2	135:22			
	135:25	138:10	O		
	138:22	139:22	O		
	154:1	156:9	O		
	157:6	157:10			
	157:12	157:12			
	157:15	157:15			
	158:3	158:5			
	158:9	158:11			
	158:12	158:16			
	159:5	171:13	O		
	189:8	189:8			
	192:18	193:3	O		
	193:16	193:18			
	193:21	194:18	O		
	194:20	195:1			
	196:4	197:11	O		
	199:3	199:12			
	199:22	200:9			

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN'S DESIGNATIONS
EXHIBIT B
Amgen's Deposition Designations for Witnesses who may be called by Designation

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
	200:13	200:14			
	200:16	200:17	O		
	200:18	200:21			
	200:22	201:24	O		
Veng-Pedersen, Peter	5:6	5:13		15:11	15:23
	7:24	15:3		27:23	30:19
	15:24	18:9		51:23	52:18
	19:17	20:14		89:16	90:20
	26:19	27:22		102:13	110:4
	34:16	42:1	O	153:5	153:16
	42:8	45:18	O	243:18	246:2
	45:24	48:4	O	267:4	267:23
	49:14	51:2	O		
	69:17	71:20			
	85:10	89:8	O		
	101:4	105:11			
	118:15	128:7	O		
	145:17	153:4			
	159:17	166:18	O		
	170:24	172:7			
	175:20	178:17			
	214:5	214:20	O		
	214:21	220:16	O		
	220:17	232:4	O		
	234:2	236:1	O		
	246:3	246:8			
	250:1	250:13			
	295:10	302:15			
USDC CASE					
Bailon, Pascal	5:13	8:23		96:18	97:9
	9:7	14:2		97:18	100:4
	20:11	20:22		154:11	157:3
	21:15	23:8	O	206:17	206:18
	25:18	27:21	O	224:14	225:3
	28:21	29:16	O		
	29:17	46:8	O		
	46:9	47:5	O		
	47:14	48:18	O		
	49:8	51:21	O		
	51:22	57:19	O		
	61:15	65:22			
	68:10	69:5	O		
	76:6	86:20	O		

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.

ROCHE'S COUNTER DESIGNATIONS AND OBJECTIONS TO AMGEN'S DESIGNATIONS
EXHIBIT B
Amgen's Deposition Designations for Witnesses who may be called by Designation

WITNESSES	AMGEN DEPOSITION DESIGNATIONS		OBJECTIONS ("O")	ROCHE COUNTER DESIGNATIONS	
	FROM	TO		FROM	TO
	87:5	88:11	O		
	88:21	96:17	O		
	96:24	102:23	O		
	103:10	107:22	O		
	108:17	124:12	O		
	125:7	145:17	O		
	146:4	152:12	O		
	154:12	162:18	O		
	163:4	189:21	O		
	195:22	199:19	O		
	199:20	200:23	O		
	203:25	206:18	O		
	211:8	213:11			
	222:18	224:13			
	227:4	227:10			
	231:21	231:24			
Baron, Joseph	25:16	28:6		171:8	171:16
	28:16	29:2		174:1	174:4
	29:10	29:16			
	34:8	35:5			
	35:15	37:1			
	42:23	43:10	O		
	52:1	52:9			
	59:7	59:13	O		
	59:16	63:20			
	72:14	73:11			
	75:21	76:5			
	85:1	85:6			
	125:3	125:16	O		
	128:5	128:13			
	130:16	131:7			
	133:7	134:8	O		
	136:24	137:19	O		
	138:11	139:9			
	139:24	141:2	O		
	142:10	142:17	O		
	155:6	155:12			
	159:1	160:10			
	169:8	170:5			
	171:17	172:19	O		
	173:6	173:24	O		
	174:5	174:16	O		
	175:23	176:1	O		

By agreement of the parties, this preliminary list of deposition designations may be modified, supplemented and/or amended, up to and including the time of final submission to the Court (or later for materials or witnesses identified during trial, as appropriate), or based on any materials (exhibits, witnesses or the like) identified by Amgen in its portions of this Pretrial Memorandum.